JPWO2020084525A5 - - Google Patents

Info

Publication number

JPWO2020084525A5

JPWO2020084525A5 JP2021515655A JP2021515655A JPWO2020084525A5 JP WO2020084525 A5 JPWO2020084525 A5 JP WO2020084525A5 JP 2021515655 A JP2021515655 A JP 2021515655A JP 2021515655 A JP2021515655 A JP 2021515655A JP WO2020084525 A5 JPWO2020084525 A5 JP WO2020084525A5

Authority

JP

Japan

Prior art keywords

treatment

pharmaceutical composition

paclitaxel

weight

composition according

Prior art date

2022-10-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 28
• 208000009458 Carcinoma in Situ Diseases 0.000 claims description 19
• 201000004933 in situ carcinoma Diseases 0.000 claims description 19
• 229930012538 Paclitaxel Natural products 0.000 claims description 18
• 229960001592 paclitaxel Drugs 0.000 claims description 18
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 18
• 229920002674 hyaluronan Polymers 0.000 claims description 16
• 229960003160 hyaluronic acid Drugs 0.000 claims description 16
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 13
• HSUDWURBWSUCOB-NUDIOSPNSA-N 7-(2′,3′′-dihydroxypropyl carbonoxy)paclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-NUDIOSPNSA-N 0.000 claims description 10
• 230000003442 weekly effect Effects 0.000 claims description 9
• 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 8
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 8
• 238000001212 derivatisation Methods 0.000 claims description 8
• 239000000126 substance Substances 0.000 claims description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 206010005006 Bladder cancer stage 0, with cancer in situ Diseases 0.000 claims description 4
• 239000000203 mixture Substances 0.000 claims description 4
• 210000003205 muscle Anatomy 0.000 claims description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
• 239000004480 active ingredient Substances 0.000 claims description 3
• 229910052799 carbon Inorganic materials 0.000 claims description 3
• 239000003085 diluting agent Substances 0.000 claims description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
• GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 claims description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
• 239000008103 glucose Substances 0.000 claims description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
• 239000000651 prodrug Substances 0.000 description 8
• 229940002612 prodrug Drugs 0.000 description 8